ATREVIA®, AN IRRESISTIBLE PROTECTION A new fluralaner alternative has been launched in the Peruvian market
Posted on 08/03/2022
Petmedica® presented its new ectoparasiticide tablets Atrevia® One and Atrevia® XR at The Westin Lima Hotel & Convention Center, in an event aimed at its elite distributors, on February 24.
Atrevia® uses fluralaner as the main component in its formula, a state-of-the-art active ingredient belonging to the isoxazoline family and now, for the first time in Peru, a monthly administration product based on this molecule was presented: Atrevia® One with effect of 1 month.
Quarterly administration presentations, Atrevia® XR, were also presented. This represents an innovation at the level of fluralaner use that allows the veterinary professional to choose the most convenient treatment.
Atrevia® One and Atrevia® XR have passed demanding field tests and demonstrated optimal performance in relation to their speed of action, safety and effectiveness against fleas, ticks and mites. In the same way, its high palatability has also been proven and achieved an acceptance of more than 96% of the dogs that participated in the studies. Truly irresistible protection!
The product is now available for veterinarians and dog lovers in our distribution channel. For more information, you can visit the page atrevia.vet or contact us through our social networks.
